IDEAYA Bio - IDYA Quarterly EPS earnings growth

Corporate company logo of IDEAYA Biosciences, Inc. (IDYA)

A snapshot of the quarterly EPS dynamics for IDEAYA Biosciences (IDYA), where the -192.80 mark indicates the current state, reveals unpredictability risks associated with early-stage drug testing. IDEAYA Biosciences relies on an asset-light model, delegating drug production to external CMO plants. Business stability depends on the outcomes of clinical trials, although current capital levels remain sufficient for operational activities.

ideayabio.com (IDYA) Year-over-year earnings per one share growth for the last 12 months: for the period 07/04/2022 - 11/14/2026

Analytical breakdowns for IDEAYA Biosciences

- share price and consensus valuation forecast:
Stock Quotes IDEAYA Biosciences, Inc.|IDYA - Analyst Forecast Prices
- issuer market value details:
Market Capitalization IDEAYA Bio|IDYA - Enterprise Value
- balance sheet net asset value indicators:
Net Assets per Single Share IDEAYA Biosciences|IDYA - Accounting Value of Company|Market Capitalization to Book Value Ratio ideayabio.com|IDYA - Company Balance Sheet Assets
- debt and liquidity data:
Total Debt to Capital IDEAYA Biosciences|IDYA - Long-Term Liabilities to Capital|Short-Term Debt to Equity Ratio IDEAYA Biosciences|IDYA - Company Cumulative Indebtedness|Debts to Book Capitalization IDEAYA Bio|IDYA - Long-Term Debt|Company Short-Term Debts IDEAYA Biosciences|Quick Liquidity Indicator ideayabio.com
- earnings and market multiples details:
IDYA - Final Profit|Future Profit IDEAYA Biosciences|IDYA - Market Price to Net Income Ratio|Forward P/E Multiple IDEAYA Bio|IDYA - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple IDEAYA Bio|IDYA - Profit before interest, taxes and amortization|Earnings per share for the last twelve months IDEAYA Biosciences|IDYA - Earnings per share for the trailing year|Quarterly EPS earnings growth ideayabio.com|IDYA - Earnings growth in current year|Net earnings per share growth forecast for next year IDEAYA Biosciences
- sales revenue and business income indicators:
IDYA - Company Annual Revenue|Company Future Sales Volume IDEAYA Biosciences, Inc.|IDYA - Price to Sales|Forward P/S Multiple IDEAYA Bio
Fundamental company valuation:IDEAYA Biosciences, Inc. - IDYA
Flagship merchandise of ideayabio.com

IDEAYA Biosciences specializes in developing precision oncology drugs utilizing synthetic lethality mechanisms. The quarterly growth dynamics of net income per share reflect the efficiency of this high-tech strategy. This metric calculates the percentage change in EPS compared to the same period last year. Growth in this metric confirms business scaling, while a slowdown signals overvaluation risks. Trend analysis allows for the determination of the optimal entry point into the asset.

Analysis of competing companies

GMAB (Genmab) - Year-over-year net earnings per share growth for the last 12 months|EXEL: Year-over-year earnings per share growth rate for the last twelve months|NUVL (Nuvalent Corp) - Quarterly EPS earnings growth|Quarterly EPS earnings growth Kymera Corp|Year-over-year earnings per share growth for the last twelve months Enliven Therapeutics (ELVN)|ORIC (oricpharma.com) - Year-over-year earnings per one share growth for the last 12 months|Quarterly EPS earnings growth RLAY (Relay Therapeutics, Inc.)|Net earnings per share growth for the trailing year Nurix Therapeutics Inc|Tyra Bio - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Verastem Corp|GLUE (Monte Rosa Therapeutics) - Year-over-year net earnings per share growth for the last 12 months|CGEM: Year-over-year earnings per share growth rate for the last twelve months|IMRX (Immuneering) - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months C4 Therapeutics Inc CCCC|Quarterly EPS earnings growth BDTX|Repare Therapeutics Inc - Year-over-year earnings per share growth for the last 12 months|PMV Pharmaceuticals - Year-over-year net earnings per share growth for the last 12 months|Year-over-year earnings per one share growth for the last 12 months KPTI|PPCB: Year-over-year net earnings per share growth for the last 12 months|Bio Green Med Solution Inc. - Year-over-year earnings per share growth rate for the last twelve months|AADI: Quarterly EPS earnings growth|Aileron Therapeutics, Inc. - Year-over-year earnings per one share growth for the last 12 months|BPMC (Blueprint Medicines Corp.) - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months GlycoMimetics Corp GLYC|Year-over-year earnings per share growth for the last twelve months SpringWorks Therapeutics, Inc. (SWTX)